Strategic Capital Options System
Biotica Bio helps later-stage or financing-stressed biotech teams explore credible non-dilutive, partnership, licensing, and structured-capital paths before dilution becomes the default answer.
One-line promise
A structured capital pathways matrix with comparables, counterparty filters, and readiness gaps—not generic fundraising advice.
Illustrative deliverable (same biology as other offers)
Product framing (illustrative): A later-stage biotech whose lead asset is a proposed IaIP blood product (hypothetical—not a real transaction or recommendation).
| Deliverable | Informed by Open Targets | Informed by Orange Book |
|---|---|---|
| Capital Pathways Matrix | Indication and mechanism crowding (OT) shapes which partners care about biology risk vs execution risk on a protein therapeutic. | Listed comparator density (OB) where applicable supports partnership economics narratives; gaps in OB trigger explicit BLA / biologics precedent workstreams so financing discussions do not assume a small-molecule comp table. |
| Executive memo | Where OT-backed story strength supports milestone timing vs where you need new data. | Where approved-product precedent is OB-documented vs must be sourced elsewhere—informational, not securities advice. |
Illustration only—full three-offer thread · Contact.
Who it is for
- Companies with identifiable assets but constrained financing options
- Boards comparing dilution vs. partnership vs. royalty-style structures
- Investors supporting portfolio company financing strategy (informational)
What problem it solves
Financing stress forces fast decisions. This offer provides a scoped map of plausible structures and what would need to be true for each path, grounded in public comparables and your stated constraints.
The method: Biotica Strategic Capital Pathways Method
- Financing context framing — Timeline, runway, covenants, and strategic constraints.
- Asset and company readiness — What is credible to take to partners or capital providers now.
- Comparable pathway mapping — Licensing, regional deals, royalty-style structures, milestone partnerships, grants/blended instruments where relevant.
- Counterparty and structure filtering — What fits this asset class and stage.
- Path scoring and recommendation — Transparent criteria; no fake precision.
The artifact: Biotica Capital Pathways Matrix
A structured matrix: options, comparables, counterparty types, readiness gaps, and recommended next steps. Delivered as an executive memo plus the matrix artifact.
Scope note
This is the narrowest product line and often follows Portfolio Intelligence once asset and market framing are clear. It is not investment banking or securities advice.
Next step
Contact with stage, lead asset, and financing pressure points. If you have not yet framed the asset competitively, start with Portfolio Intelligence System.
Strategic and educational use only—not legal, tax, or investment advice.